作者
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlesi, John C Morris, Taofeek K Owonikoko, Daniel SW Tan, Oliver Gautschi, Jared Weiss, Christelle De La Fouchardiere, Mark E Burkard, Janessa Laskin, Matthew H Taylor, Matthias Kroiss, Jacques Medioni, Jonathan W Goldman, Todd M Bauer, Benjamin Levy, Viola W Zhu, Nehal Lakhani, Victor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H Shah, Maria E Cabanillas
发表日期
2020/8/27
期刊
New England Journal of Medicine
卷号
383
期号
9
页码范围
825-835
出版商
Massachusetts Medical Society
简介
Background
RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown.
Methods
We enrolled patients with RET-mutant medullary thyroid cancer with or without previous vandetanib or cabozantinib treatment, as well as those with previously treated RET fusion–positive thyroid cancer, in a phase 1–2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response), as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.
Results
In the first 55 consecutively enrolled patients with RET-mutant medullary thyroid cancer who had previously received vandetanib, cabozantinib, or both, the percentage who had a response was 69 …
学术搜索中的文章
LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang… - New England Journal of Medicine, 2020